| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2010.31.6950 |
| P8608 | Fatcat ID | release_xnezc4mk75hnjbj6ib7iwejk64 |
| P932 | PMC publication ID | 3107749 |
| P698 | PubMed publication ID | 21555689 |
| P5875 | ResearchGate publication ID | 51110886 |
| P50 | author | Kelly K Hunt | Q90520703 |
| Laura Esserman | Q91960202 | ||
| Vera J Suman | Q96186734 | ||
| Gildy V Babiera | Q114440921 | ||
| P2093 | author name string | Li Lin | |
| Aleix Prat | |||
| Marilyn Leitch | |||
| D Craig Allred | |||
| Matthew J Ellis | |||
| John A Olson | |||
| Jacqueline Snider | |||
| Jeremy Hoog | |||
| Jingqin Luo | |||
| Julie Margenthaler | |||
| Katherine DeSchryver | |||
| P Kelly Marcom | |||
| Joel S Parker | |||
| Mark A Watson | |||
| Gary W Unzeitig | |||
| Joseph M Guenther | |||
| P2860 | cites work | Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial | Q24597456 |
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Supervised risk predictor of breast cancer based on intrinsic subtypes | Q29617404 | ||
| Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool | Q34253719 | ||
| A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer | Q34268261 | ||
| A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer | Q34563755 | ||
| Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics | Q36916152 | ||
| Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial | Q36932728 | ||
| Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer | Q37584869 | ||
| Prognostic and predictive factors in breast cancer by immunohistochemical analysis. | Q40866567 | ||
| Breast cancer molecular profiling with single sample predictors: a retrospective analysis | Q42467730 | ||
| Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial | Q43739514 | ||
| Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study | Q43873472 | ||
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial | Q44045676 | ||
| Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status | Q44618254 | ||
| Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival | Q45258324 | ||
| Neoadjuvant endocrine therapy for breast cancer: more questions than answers | Q46585153 | ||
| Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial | Q46585161 | ||
| Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer | Q46674525 | ||
| Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. | Q50666942 | ||
| Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer | Q57579999 | ||
| Clinical implementation of the intrinsic subtypes of breast cancer | Q59565395 | ||
| Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 | Q73494751 | ||
| Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer | Q79572358 | ||
| Preoperative systemic chemotherapy and pathologic assessment of response | Q81453731 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| anastrozole | Q419143 | ||
| biomarker | Q864574 | ||
| P304 | page(s) | 2342-2349 | |
| P577 | publication date | 2011-05-09 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas | |
| P478 | volume | 29 |
| Q39141610 | A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. |
| Q64085234 | A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer |
| Q36533964 | A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688 |
| Q47565435 | A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. |
| Q38015026 | A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints |
| Q35023875 | A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients |
| Q47107430 | A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity |
| Q55346913 | A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells |
| Q36903310 | A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. |
| Q34347274 | A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer |
| Q37158337 | A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers |
| Q90045073 | Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer |
| Q39089103 | Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527 |
| Q38206546 | Advances in the approach to novel drug clinical development for breast cancer |
| Q38997213 | Age-related Disparity: Breast Cancer in the Elderly |
| Q34359310 | Age-specific changes in intrinsic breast cancer subtypes: a focus on older women |
| Q37463125 | An international Ki67 reproducibility study |
| Q40417660 | An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors |
| Q38464311 | Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer. |
| Q37166239 | Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers |
| Q83297097 | Aromatase inhibitors in premenopausal breast cancer |
| Q35552069 | Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group |
| Q44908519 | Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women |
| Q38933076 | Bilateral Salpingo-Oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors |
| Q38696790 | Biomarker assessment and molecular testing for prognostication in breast cancer |
| Q38148495 | Breast cancer management in the elderly |
| Q38195542 | Breast conservation therapy after neoadjuvant chemotherapy: optimization of a multimodality approach |
| Q42481201 | Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers |
| Q36069527 | CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials |
| Q55468048 | Clinical Significance of the Neutrophil-to-Lymphocyte Ratio in Endocrine Therapy for Stage IV Breast Cancer. |
| Q36287107 | Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer |
| Q36594068 | Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas |
| Q26800996 | Clinical implications of the intrinsic molecular subtypes of breast cancer |
| Q35960231 | Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy |
| Q90665335 | Comparative Age-Based Prospective Multi-Institutional Observations of 12,367 Patients Enrolled to the American College of Surgeons Oncology Group (ACOSOG) Z901101 Trials (Alliance) |
| Q88792280 | Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers |
| Q36337751 | Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. |
| Q92501000 | Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial |
| Q57113531 | Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer |
| Q55275883 | Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer. |
| Q26795751 | Current medical treatment of estrogen receptor-positive breast cancer |
| Q49558301 | Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. |
| Q91693727 | De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study |
| Q41136265 | Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease |
| Q34334262 | Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. |
| Q38638437 | Do all aromatase inhibitors have similar efficacy and safety? |
| Q30317067 | ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† |
| Q49035643 | Early Surrogate Markers of Treatment Activity: Where Are We Now? |
| Q35653956 | Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy |
| Q35445037 | Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada |
| Q36419177 | Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. |
| Q59072640 | Endocrine Resistance in Breast Cancer |
| Q47097891 | Endocrine sensitivity of estrogen receptor-positive breast cancer is negatively correlated with aspartate-β-hydroxylase expression |
| Q24621116 | Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts |
| Q33585930 | Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer |
| Q34991926 | Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer |
| Q37094009 | Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics |
| Q89480730 | Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy |
| Q61809135 | Evaluating mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer |
| Q43591690 | Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer |
| Q96576684 | Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic |
| Q27028211 | Exemestane for breast cancer prevention: a critical shift? |
| Q35949285 | Exemestane in the prevention setting |
| Q31150676 | FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients |
| Q58796572 | Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer |
| Q37169835 | Gene expression profiling: changing face of breast cancer classification and management |
| Q26862681 | Genomic profiling in luminal breast cancer |
| Q34184763 | High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer |
| Q64905956 | Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer. |
| Q37992403 | Hormonal therapy in breast cancer: a model disease for the personalization of cancer care |
| Q33712476 | Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer |
| Q49580516 | Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype. |
| Q92354821 | Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients |
| Q53674063 | Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers. |
| Q55208892 | Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. |
| Q38765017 | Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer |
| Q36889647 | Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer |
| Q92055163 | Indications for Neoadjuvant Systemic Therapy for Breast Cancer |
| Q42506362 | Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. |
| Q38222834 | Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer |
| Q58698990 | Ki 67 assessment in breast cancer in an Egyptian population: a comparative study between manual assessment on optical microscopy and digital quantitative assessment |
| Q46216934 | Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). |
| Q35794915 | Landscape of neoadjuvant therapy for breast cancer |
| Q53183982 | Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer. |
| Q48348546 | Letrozole: advancing hormone therapy in breast cancer |
| Q36739182 | Long-term efficacy and safety of exemestane in the treatment of breast cancer |
| Q101353570 | Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial |
| Q37683512 | Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. |
| Q35143049 | Longitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy |
| Q38628334 | Loss of MutL Disrupts Chk2-dependent Cell Cycle Control Through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer |
| Q57113322 | Luminal A Breast Cancer and Molecular Assays: A Review |
| Q41201081 | Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience |
| Q38350939 | Management of locally advanced breast cancer-perspectives and future directions |
| Q38439266 | Mechanisms of aromatase inhibitor resistance. |
| Q95406818 | Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer |
| Q47162938 | Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy |
| Q34120668 | Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer |
| Q38236904 | Molecular markers for breast cancer diagnosis, prognosis and targeted therapy |
| Q34594645 | Molecular pathways: extracting medical knowledge from high-throughput genomic data |
| Q37208553 | Mutational analysis of breast cancer: guiding personalized treatments |
| Q50093673 | NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer |
| Q38883281 | Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. |
| Q57495764 | Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field |
| Q39242605 | Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States. |
| Q38658509 | Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. |
| Q39299810 | Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery |
| Q26773012 | Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives |
| Q92685576 | Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer |
| Q37577665 | Neoadjuvant endocrine treatment for breast cancer: from bedside to bench and back again? |
| Q48247756 | Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). |
| Q49622309 | Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict's value |
| Q51320601 | Neoadjuvant therapy for ER-positive breast cancers. |
| Q27694514 | Neoadjuvant therapy in the treatment of breast cancer |
| Q45140936 | Neoadjuvant treatment of breast cancer. |
| Q36897982 | Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR-Positive Breast Cancer |
| Q64272230 | Network-guided prediction of aromatase inhibitor response in breast cancer |
| Q90110379 | Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer |
| Q53692408 | Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer. |
| Q33925038 | Optimizing the use of neoadjuvant endocrine therapy |
| Q34433549 | PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. |
| Q34346725 | Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance |
| Q89996784 | Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance) |
| Q35115517 | Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR) |
| Q37123877 | Potential applications for biguanides in oncology |
| Q36989546 | Practical implications of gene-expression-based assays for breast oncologists. |
| Q46143861 | Pre-operative Endocrine Therapy |
| Q94547024 | Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer |
| Q36344573 | Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging |
| Q97884681 | Predicting therapeutic efficacy of endocrine therapy for stage IV breast cancer by tumor-infiltrating lymphocytes |
| Q89455386 | Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials |
| Q35948773 | Predictors of pathological complete response to neoadjuvant chemotherapy in stage II and III breast cancer: The impact of chemotherapeutic regimen |
| Q36350006 | Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients |
| Q61454343 | Primary medical therapy and breast conservation treatment: the medical oncology perspective |
| Q38155673 | Primary therapy in breast cancer: what have we learned from landmark trials? |
| Q38778532 | Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer |
| Q36494250 | Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer |
| Q98613770 | Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer |
| Q36457511 | Progress in endocrine approaches to the treatment and prevention of breast cancer |
| Q55137873 | Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature. |
| Q51697267 | Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French |
| Q34486201 | Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition |
| Q90203353 | Research-based PAM50 signature and long-term breast cancer survival |
| Q28074295 | Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer |
| Q91981752 | Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial |
| Q46079920 | Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting |
| Q93167667 | SEOM clinical guidelines in early stage breast cancer (2018) |
| Q34348721 | Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. |
| Q39167766 | Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials |
| Q36253304 | Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis |
| Q57495766 | Standard Neoadjuvant Treatment in Early/Locally Advanced Breast Cancer |
| Q38735015 | Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts |
| Q24194629 | Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus) |
| Q37992692 | Surgical considerations in patients receiving neoadjuvant systemic therapy |
| Q35858051 | Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. |
| Q26786704 | The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer |
| Q54481775 | The current state of breast cancer classification. |
| Q40568396 | The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer |
| Q26746034 | The role of preoperative systemic treatment in patients with breast cancer |
| Q35693300 | The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies |
| Q47638243 | Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. |
| Q91981772 | Time for a shift in molecular down staging in luminal breast cancer |
| Q31132822 | Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study. |
| Q36915182 | Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy |
| Q39100596 | Update of the Phase III trial 'GRETA' of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women |
| Q36947842 | Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer |
| Q35909568 | Use of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer at German Breast Cancer Centers and University Hospitals - Results of an Enquiry (Adjuvant Endocrine Therapy Enquiry). |
| Q34174466 | Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer |
| Q45057063 | Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial |
| Q64971109 | Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. |
| Q34485047 | Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations. |
| Q28269291 | Whole-genome analysis informs breast cancer response to aromatase inhibition |
Search more.